Every year, from April onwards, hand, foot and mouth disease broke out.The disease has the ability to infect quickly, high fevers, intense convulsions, leading to death in some cases ...
According to MSc Phan Thi Ngoc Uyen (Pasteur Institute of Ho Chi Minh City), hand, foot and mouth disease is the infectious disease of Group B, spread quickly, can be fatal, but the danger level is lower than Group A.In Vietnam, the first infection of EV71 virus - strain causes severe complications in 2003.There is the highest number of cases and death.
In Vietnam, hand, foot and mouth disease circulates all year round across the country, with the most concentrated incidence in the Southeast.
In 2025, in the first 19 weeks, the southern region recorded 14,600 cases, no death.Notably, this year's translation tends to slow down in the last 4 weeks, with an average of 1,300 cases/week.
Also according to Dr. Ngoc Uyen, EV71 virus, especially the B5 and C4 subgroups - is the main agent causing serious illness and death.Data from Pasteur Institute of Ho Chi Minh City and health units show that, when EV71 dominated, the mortality rate also increased, as happened in the translation in 2011, 2021 and 2023.
Analysis of 94 deaths from hand, foot and mouth from 2012–2022 showed that: 94% of children died under 5 years old, the average age was 2 years old, men accounted for about 60%.In particular, schools and households are identified as two hot spots spreading the disease.
A study by the Pasteur Institute of Ho Chi Minh City showed that the rate of attacks in households with people with hand, foot and mouth up to 25.5%, and 8% of people with no symptoms still have positive test results.
Facing urgency in need of a vaccine to prevent hand, foot and mouth disease, Pasteur Institute of Ho Chi Minh City recently announced the results of clinical trials to prevent hand, foot and mouth disease (EV71) phase 3.
According to Dr. Luong Chan Quang - Head of the Department of Control and Prevention of Disease, Pasteur Institute of Ho Chi Minh City, research team from Vietnam and Taiwan (China) announced the protection up to 99.21%.
After three years of implementation in Vietnam and Taiwan (China), phase 3 clinical trial research for EV71 vaccine manufactured by Medigen Company (Taiwan) ended in November last year.
Test vaccine is a total inactivated vaccine of EV71, supplementing aluminum excipients, made from the EV71 virus strain (Genotype B4) that has been licensed to use in Taiwan (China) from two years ago.
Researching the collection of 3,993 children from 2 months to under 6 years old, divided into two groups: one group of vaccines, a placebo group (only aluminum excipients, no virus component).Vaccine is injected two doses, 28 days apart.Protection efficiency is monitored within one year from 28 days after the second nose.
The results showed that, of 71 cases of EV71 infection, 70 shifts belong to the placebo group, only one shift belonging to the vaccine group.Protection effect reaches 99.21% (95% reliability ranges from 94.3% or more).In particular, the vaccine gives 100% validity in most age groups, except for 2–11 months of age.
"The safety of the vaccine is carefully evaluated. The local and post -injection side effects are recorded within 7 days. The results show that the side effect rate between the vaccine and the placebo group is similar, mainly light and transient, there is no serious events related to the vaccine.
